Engflag

Urispas 200mg

Quick links to important sections

Urispas 200mg

Urispas 200mg_IT

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Urispas 200mg

Quick Facts

Property Description
Active ingredient Flavoxate hydrochloride
Form Film-coated tablet (200 mg strength)
Pharmacological class Musculotropic Antispasmodic / Urological Agent
Common use Symptomatic relief of bladder spasm and urgency
Origin Synthetic compound

What is Urispas 200mg and Its Active Ingredient?

Urispas 200mg is a prescription medicine formulated for oral administration, with the key active ingredient being Flavoxate hydrochloride. The drug is a synthetic compound manufactured as a single-ingredient product, where its pharmacological effects derive from the properties of Flavoxate at the standardized 200mg strength. The Flavoxate component, which is a derivative of a tertiary amine, is clinically recognized for its role as a urinary antispasmodic.

Classification: What Type of Antispasmodic is Flavoxate?

Flavoxate is classified within the pharmacological class of antispasmodics, specifically operating as a musculotropic antispasmodic due to its direct action on muscle fibers. This class operates through a distinct mechanism. The defining characteristic of this compound is its pronounced specific affinity for the detrusor muscle, which forms the wall of the bladder. This targeted action makes the agent a specialized tool for addressing muscle-related issues in the urinary system.

General Purpose and Form

The general purpose of Flavoxate is to provide symptomatic relief by reducing the excessive, involuntary tightening known as bladder spasm. By promoting smooth muscle relaxation, the medication directly helps to alleviate common, disruptive sensations, including dysuria (painful urination) and the sudden, frequent urge to urinate (urgency).

The medication is reliably supplied as a film-coated tablet, a stable pharmaceutical preparation ensuring accurate dosing and ease of oral administration. It is used for relieving symptoms such as painful, frequent, or nighttime urination, with a therapeutic role centered on controlling the disruptive muscular activity of the bladder.

Regulatory References

  1. Flavoxate - LiverTox - NIH
  2. Flavoxate: MedlinePlus Drug Information

What side effects are possible with Urispas 200mg?

Possible Side Effects and Safety Information

Urispas (flavoxate hydrochloride) is associated with documented adverse reactions that affect multiple body systems, including gastrointestinal, nervous, and ocular systems. The frequency of these effects ranges from Common to Not Known, as established by governmental regulatory bodies.

Adverse Reaction Category Examples of Reported Effects
Gastrointestinal Nausea (Common), vomiting, dry mouth, dyspepsia, gastric pain.
Nervous System Somnolence (Uncommon), headache, vertigo, nervousness, mental confusion (particularly in the elderly).
Ophthalmic Blurred vision (Uncommon), increased ocular tension, disturbance in eye accommodation, glaucoma (Not known).
Cardiac Palpitations, tachycardia (Not known).
Skin & Immune Rash (Uncommon), pruritus, urticaria, hypersensitivity reactions, anaphylactic shock (Not known).

Serious and Clinically Significant Safety Considerations

The most serious, though rare or not-known frequency, adverse reactions reported include Anaphylactic shock, Jaundice, and signs of Liver disorder. The drug is strictly contraindicated in patients with specific pre-existing conditions:

  • Obstructive gastrointestinal conditions (pyloric or duodenal obstruction, ileus).
  • Gastrointestinal hemorrhage.
  • Obstructive uropathies of the lower urinary tract or urinary retention.
  • Glaucoma or Myasthenia Gravis.

Population-Specific and Use Limitations

  • Pediatric Use: Safety and effectiveness have not been established for children under 12 years of age; use in this age group is not recommended.
  • Elderly: Caution is advised, as mental confusion may occur, particularly in older patients.
  • General Precaution: Due to the potential for drowsiness and blurred vision, patients are cautioned against driving or operating machinery until they understand how the medication affects them. The safety of the medicine during pregnancy and lactation has not been established, and its use is not recommended during these periods.

Overdose and Emergency Response

The official regulatory documents specify that an overdose of Urispas 200mg (Flavoxate hydrochloride) is primarily associated with pronounced effects on the central nervous system (CNS). Documented manifestations include signs such as severe drowsiness and severe dizziness, along with altered mental states like hallucinations, unusual excitement, and mental confusion. This confusion is noted to occur especially in the elderly population. Other documented physical signs may include fever, flushing of the face, and blurred vision.

In severe overdose scenarios, life-threatening clinical manifestations such as convulsions or seizures, collapse, and troubled breathing have been documented. The official guidance requires individuals to seek immediate medical attention upon suspicion of overdose.

When to Seek Urgent Help

The regulatory instructions mandate contacting emergency services (911) immediately if the affected individual is exhibiting life-threatening symptoms. This includes if the individual has collapsed, had a seizure, or is experiencing trouble breathing or unresponsiveness. Contacting the Poison Control Helpline is also required.

Clinical management is officially described as symptomatic and supportive treatment. Regulatory information notes that it is not known whether Flavoxate hydrochloride is dialyzable, and no specific antidote is documented.

Therapeutic Uses of Urispas 200mg

Urispas 200mg is primarily intended to support the management of uncomfortable symptoms related to irritation in the lower urinary tract. The medication may assist in moderating difficulties such as the sudden, strong need to pass urine (urinary urgency) and the discomfort associated with painful urination (dysuria).

This medicine helps manage symptoms across various clinical scenarios, including those linked to cystitis, urethritis, and prostatitis. It is used to address the need to urinate frequently during the day (frequency) and at night (nocturia). The core benefit is an improvement in daily comfort and control over these bothersome symptoms, which may also include muscular spasms that may follow certain urological procedures.

Quick Fact: Relief for Urinary Urgency and Dysuria

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

The eligibility for using Urispas 200mg (flavoxate hydrochloride) is strictly defined by regulatory documents, primarily based on age and the presence of specific contraindicating medical conditions.

Population Status Regulatory Rule
Approved Age Group Use is established for adults and adolescents aged 12 years and older.
Pediatric Restriction Use is not recommended for children under 12 years because safety and efficacy have not been established.
Use in Pregnancy Use is generally avoided or restricted to situations where the benefit clearly outweighs potential risk.
Use while Breastfeeding Should not be used, as it is unknown if the drug or its metabolites are excreted into human milk.
Conditional Use Caution is required in patients with renal impairment and in older adults, who may be more susceptible to certain effects.

Absolute Contraindications (Must Not Use)

Individuals are formally prohibited from using Urispas 200mg if they have:

  • Obstructive Disorders: Gastrointestinal obstructive conditions (e.g., ileus, pyloric obstruction) or obstructive uropathies of the lower urinary tract (e.g., urinary retention).
  • Specific Clinical Conditions: Gastrointestinal hemorrhage, achalasia, myasthenia gravis, angle-closure glaucoma, or known hypersensitivity to the active ingredient.
  • Metabolic Disorders: Rare hereditary problems of galactose intolerance or total lactase deficiency (due to formulation excipients).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Urispas (Flavoxate hydrochloride) defines interaction patterns that primarily involve pharmacodynamic effects related to smooth muscle activity and the autonomic nervous system. The most significant concern involves the potential for additive effects when combined with specific substances.

Interaction Scope Classification and Restriction
Interacting Drug Categories Anticholinergic medicinal products, and agents that inhibit gastrointestinal motility.
Substance Restriction Consumption of alcohol is documented to increase the risk of drowsiness and other central nervous system effects.
Population Note Central nervous system adverse effects, such as mental confusion, may be especially likely to occur in elderly patients.

Formal Combination Restrictions

Co-administration with certain agents is addressed by high-level regulatory constraints:

  • Pramlintide: This combination is contraindicated due to the potential for a synergistic inhibition of gastrointestinal motility.
  • Secretin: Flavoxate may cause a hyporesponse to Secretin stimulation testing. To prevent this effect, anticholinergic drugs must be discontinued for a minimum of five half-lives before the test is performed.

Exposure-Modifying Interactions

The regulatory profile notes that the drug's action on the gastrointestinal tract can affect the absorption of other oral medicines. Flavoxate may decrease the plasma concentrations of the oral form of Aripiprazole by inhibiting its absorption due to delayed gastric emptying. Furthermore, the combination with solid oral dosage forms of Potassium Chloride or Potassium Citrate is generally not recommended in some labels due to synergistic risks of GI motility inhibition.

These statements collectively structure the product's official interaction profile, highlighting constraints necessary to manage risks associated with additive anticholinergic and GI motility effects.

Mechanism of Action

Flavoxate functions primarily as a direct-acting smooth muscle relaxant and possesses inherent anticholinergic properties. Its principal biological target is the detrusor muscle within the urinary bladder. The compound acts as a non-competitive antagonist of muscarinic acetylcholine receptors, showing preferential modulation of the M3 subtype located on the smooth muscle cell surface.

This interference with acetylcholine binding reduces the signal transmission required for cellular excitation. The resultant pathway modulation involves a decrease in the intracellular influx of calcium ions (Ca^2+). This molecular event subsequently modulates the interaction between actin and myosin proteins, which form the contractile apparatus within the smooth muscle cell. The mechanistic cascade concludes with the system-level physiological consequence of a reduction in basal muscle tone and a decrease in the amplitude of spontaneous detrusor contractions.

Dosage and Administration Information

How Urispas 200mg is Used: Administration Guidelines

Urispas (flavoxate hydrochloride) is a medication administered exclusively via the oral route as a film-coated tablet, following a dosing pattern intended to provide continuous effect. The usage principles dictate the schedule and conditions for proper intake.

Standard Dosing and Frequency

Administration Scope Standard Usage Principle
Route of Administration Oral route
Dosing Schedule (Adults) Typically 100 mg to 200 mg per dose
Frequency Pattern Taken three or four times a day (divided daily use)
Dose Adjustment The dose may be reduced as symptoms show improvement.

Administration Conditions and Restrictions

The correct intake of the tablet is associated with specific conditions:

  • Timing with Food: The tablet is to be taken after a meal.
  • Tablet Form: The film-coated tablet must be swallowed whole with water and should not be crushed or broken, ensuring its integrity upon administration.
  • Missed Dose: If a dose is missed, a double dose should not be taken. Instead, the user should continue with the next regularly scheduled dose at the usual time.

Use in Specific Populations

Use of flavoxate is not established or recommended for children under the age of 12 years. Additionally, caution is required when the medication is administered to patients with impaired renal function, reflecting the importance of kidney function in the drug's metabolism.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Urispas 200mg (Flavoxate)

Evidence for Acute Lower Urinary Tract Symptoms (LUTS)

Clinical research exploring how symptoms change over time has examined flavoxate in trials including adults and children over 12 who have lower urinary tract irritation, often associated with conditions such as cystitis, urethritis, and prostatitis. Studies conducted during periods of increased symptom activity include short-term Randomized Controlled Trials (RCTs) and comparative clinical trials. These studies primarily focused on patient-reported outcomes describing perceived discomfort, specifically outcomes related to painful urination (dysuria), urinary urgency, and nocturia. The existing evidence base for this indication is categorized as having Moderate certainty. Follow-up durations were limited in many of the primary studies.

Evidence in Overactive Bladder (OAB) Symptom Management

The evidence landscape for flavoxate in managing symptoms related to Overactive Bladder (OAB) was evaluated in trials that included controlled double-blind studies and meta-analyses. Research explored changes in objective urodynamic parameters, which involve monitoring physiological strain such as bladder volume capacity and the frequency of involuntary detrusor contractions. Trials reported objective measurements indicating changes in bladder function and described patterns of reported symptomatic change across studies. The overall evidence for OAB is categorized as having Low to Moderate certainty. Comparative evidence is lacking, meaning there is limited recent research directly comparing flavoxate to newer standard treatments.

Duration of Evidence: Short-Term vs. Long-Term Follow-up

The existing body of research for flavoxate primarily consists of studies designed to assess short-term or episodic symptom patterns during acute treatment phases. Research provides context about group patterns but does not offer predictions for individual patient outcomes. Evidence for long-term outcomes, maintenance, or durability of change is scarce. Data for extended, long-term outcomes are not well characterized. There is limited information for long-term outcomes regarding the sustained symptomatic relief or functional changes, meaning the overall evidence base is weighted heavily toward short-term observations.

Key Studies & References Flavoxate Hydrochloride Tablets, USP (Official Prescribing Information/Package Insert)

Frequently Asked Questions (FAQ)

Common questions about Urispas 200mg (FAQ)

Q: Can Urispas affect the absorption of my other medications?

Official labeling documents state that Urispas can affect the way your body handles other medicines taken by mouth. This is because it has a slowing effect on the gastrointestinal tract, which may decrease the absorption of other oral medications. For example, this effect has been noted to potentially decrease the plasma (blood) concentrations of Aripiprazole.

Q: How long does it take for Urispas to start working and show effect?

According to clinical data from regulatory sources, the onset of action, when the drug begins to have a noticeable effect, typically occurs around 55 minutes after the tablet is taken. The maximum concentration of the drug in the body is generally reached within approximately two hours.

Q: Is Urispas a long-term treatment or is it for short-term use?

Urispas is officially indicated for the symptomatic relief of acute lower urinary tract symptoms. The available research on the drug has mainly focused on short-term use and acute symptom patterns. Information regarding the safety and effectiveness of Urispas for extended, long-term outcomes is not well-established in the current regulatory documents.

Q: What should I do if I accidentally take too much Urispas?

Symptoms of taking too much Urispas can include severe drowsiness, fever, blurred vision, or mental confusion. Regulatory guidance on overdose generally advises that a healthcare professional or a poison control center be contacted. Any treatment required for an overdose is expected to be managed by a medical professional.

Q: Are there any dietary restrictions I need to follow while taking this medication?

Regulatory documents do not mention any general food or dietary restrictions to follow while taking Urispas. However, the official labeling does specify a restriction on the consumption of alcohol. Alcohol can increase the risk of side effects like drowsiness and other central nervous system effects when combined with this medication.

How should Urispas 200mg be stored and disposed of?

Storage Requirements

Urispas (flavoxate hydrochloride) 200mg tablets must be stored under specific environmental controls to maintain product stability, as directed by official labeling. The tablets require storage at Controlled Room Temperature, defined as 20^circ to 25 C (68^circ to 77 F). The medication must be protected from both moisture and direct light. Storage should prevent exposure to excessive heat or freezing.

Packaging and Safety

Tablets must be dispensed and kept in a tight, light-resistant container. To ensure protection from light, the blister strips must remain inside the outer carton. As a mandatory safety requirement, all medication must be stored securely and kept out of the sight and reach of children.

Disposal Instructions

Expired or unused tablets should not be disposed of via household waste or flushed down the toilet (wastewater). Official guidance instructs returning all unneeded medicine to a pharmacist or utilizing an approved drug take-back program for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Urispas 200mg found in:

A-Z Index: